Sherbrooke Park Advisers LLC Takes $868,000 Position in Zoetis Inc. (NYSE:ZTS)

Sherbrooke Park Advisers LLC bought a new position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 5,325 shares of the company's stock, valued at approximately $868,000.

A number of other hedge funds have also modified their holdings of ZTS. Callahan Advisors LLC boosted its holdings in shares of Zoetis by 90.4% during the 4th quarter. Callahan Advisors LLC now owns 13,105 shares of the company's stock worth $2,135,000 after purchasing an additional 6,221 shares during the last quarter. CIBC Asset Management Inc lifted its position in Zoetis by 24.1% during the fourth quarter. CIBC Asset Management Inc now owns 237,369 shares of the company's stock worth $38,617,000 after buying an additional 46,050 shares in the last quarter. Schroder Investment Management Group lifted its position in Zoetis by 2.6% during the fourth quarter. Schroder Investment Management Group now owns 245,726 shares of the company's stock worth $40,036,000 after buying an additional 6,169 shares in the last quarter. Vanguard Group Inc. grew its holdings in Zoetis by 0.3% in the 4th quarter. Vanguard Group Inc. now owns 41,366,877 shares of the company's stock valued at $6,739,905,000 after buying an additional 120,158 shares in the last quarter. Finally, Alberta Investment Management Corp increased its stake in shares of Zoetis by 2,050.0% in the 4th quarter. Alberta Investment Management Corp now owns 30,100 shares of the company's stock worth $4,904,000 after acquiring an additional 28,700 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Zoetis

In related news, EVP Roxanne Lagano sold 326 shares of the business's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $170.00, for a total value of $55,420.00. Following the completion of the sale, the executive vice president now directly owns 15,781 shares of the company's stock, valued at $2,682,770. The trade was a 2.02% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Willie M. Reed sold 1,210 shares of the business's stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total transaction of $201,029.40. Following the completion of the sale, the director now directly owns 11,245 shares of the company's stock, valued at approximately $1,868,244.30. This trade represents a 9.71% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.18% of the company's stock.

Zoetis Stock Up 0.5%

ZTS stock traded up $0.86 during mid-day trading on Monday, reaching $163.90. The company had a trading volume of 2,077,362 shares, compared to its average volume of 2,514,255. The firm has a fifty day simple moving average of $156.46 and a 200 day simple moving average of $165.22. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. The company has a market capitalization of $72.97 billion, a price-to-earnings ratio of 29.96, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94. Zoetis Inc. has a fifty-two week low of $139.70 and a fifty-two week high of $200.33.

Zoetis (NYSE:ZTS - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.08. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The firm had revenue of $2.22 billion for the quarter, compared to analysts' expectations of $2.20 billion. During the same quarter last year, the company earned $1.38 earnings per share. The firm's revenue was up 1.4% compared to the same quarter last year. Analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

ZTS has been the topic of several recent research reports. Barclays boosted their price target on shares of Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a research report on Friday, February 14th. StockNews.com upgraded shares of Zoetis from a "hold" rating to a "buy" rating in a report on Friday, March 7th. UBS Group cut their price target on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a report on Wednesday, May 7th. Piper Sandler upped their price objective on Zoetis from $205.00 to $210.00 and gave the company an "overweight" rating in a report on Monday, May 12th. Finally, Morgan Stanley reduced their target price on Zoetis from $243.00 to $238.00 and set an "overweight" rating on the stock in a research report on Friday, February 14th. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $212.75.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.